Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis

Paolo Strati, Maen Abdelrahim, Umut Selamet, Valda D. Page, Sherry A. Pierce, Srdan Verstovsek, Ala Abudayyeh

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Recent evidence suggests that renal dysfunction may be a direct consequence of primary myelofibrosis (PMF). We performed a retrospective analysis of 100 patients with previously untreated PMF, receiving frontline treatment with single agent ruxolitinib, and compared them to 105 patients, receiving frontline treatment with a non-ruxolitinib-based therapy, matched by age, sex, DIPSS plus, and estimated glomerular filtration rate (eGFR). Use of ruxolitinib associated with a significantly higher rate of renal improvement (RI) > 10% (73% vs 50%, p = 0.01) confirmed on multivariate analysis (MVA) [odds ratio 3, 95% confidence interval (CI) 1.6–5.5, p < 0.001]. After a median follow-up of 41 months (range, 1–159 months), median failure-free survival (FFS) was 14 months (range, 1–117 months). Achievement of a RI > 10% maintained its independent association with prolonged FFS on MVA (hazard ratio 1.4, 95% CI 1.1–2, p = 0.02). Ruxolitinib can significantly improve renal function in patients with PMF, significantly impacting failure-free survival.

Original languageEnglish (US)
Pages (from-to)1611-1616
Number of pages6
JournalAnnals of Hematology
Issue number7
StatePublished - Jul 1 2019


  • PMF
  • Renal function
  • Ruxolitinib

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis'. Together they form a unique fingerprint.

Cite this